CS231295 is a brain-penetrant Aurora B selective inhibitor exclusively discovered by the company with global patent protection. Aurora B is specifically overexpressed in various tumors and is associated with tumor prognosis. Inhibition of Aurora B may result in targeted tumor-killing effects. For tumors with RB1 deletion and other potential gene deletions, CS231295 can produce a synthetic lethal effect and deliver targeted efficacy. Meanwhile, CS231295 exhibits significant anti-tumor angiogenesis activity, enabling broad-spectrum anti-tumor effects. Furthermore, CS231295 demonstrates good blood-brain barrier permeability, showing clear therapeutic advantages for both primary and metastatic brain tumors, and holds strong application potential in the treatment of malignant brain tumors and brain metastases. Leveraging its unique mechanism and chemical structure, CS231295 exhibits synergistic therapeutic effects when combined with various treatments such as chemotherapy, targeted therapy, and tumor immunotherapy. In preclinical studies, CS231295 has demonstrated significant pharmacodynamic activity, desirable pharmacokinetic characteristics, and favorable safety.

• On May 21, 2025, the first patient was enrolled in the Chinese clinical trial of CS231295.
• On July 31, 2025, the clinical trial of CS231295 was approved by the U.S. FDA.

Currently, there are no drugs with similar design that have entered the clinical trial stage globally.